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Erdheim Chester disease (ECD) is a rare, non-Langerhans' cell histiocytic neoplastic 
disorder that usually presents in patients in their fifties.  ECD often presents as a 
multi-system macrophagic infiltration and common sites of involvement are the 
central nervous system, cardiovascular system, respiratory system, retroperitoneum, 
and skin.  Extra-skeletal involvement is usually responsible for death due to 
secondary complications and ECD has had until recently an extremely poor 
prognosis (vide infra), with less than half of patients surviving three years (1).    
 
The exact aetiology of ECD is unknown, but recent molecular studies have shown 
that that over half of the cases contain a BRAF V600 mutation (2).  However, 
Diamond et al. recently reported a single case of ECD with an NRAS codon 61 
substitution in the absence of a BRAF mutation (3). Here we report the second case 
of ECD with an NRAS mutation identified through review of the pathology archives: 
we identified a case of a 77 year-old retired man with multiple co-morbidities who 
presented with progressive bone pain around the right knee. Radiographs showed 
areas of increased density in both tibiae and the right femur, but no widespread bony 
lesions.  In addition, T1-weighted magnetic resonance imaging showed confluent 
areas of abnormal marrow signal in the femur and tibia, with heterogeneous fat 
adjacent to the femoral lesion (Figure 1).  Due to the patient’s frailty, serial imaging 
was not performed.   
 
Microscopic examination of a needle biopsy specimen taken from the presenting 
bony lesion in the right tibia showed diffuse chronic macrophagic infiltration of bone 
with associated bone remodelling (Figure 1). In spite of presentation with only 
localised disease, ECD was suggested.  The patient did not receive active treatment 
for ECD due to co-morbidities, including bladder cancer. 
 
To characterise further the abnormal infiltrate in bone, a next generation sequencing 
approach was used to examine mutations in common oncogenes. 10ng of DNA was 
extracted from three 10µm formalin-fixed paraffin-embedded sections from the 
needle biopsy, and examination of the haematoxylin and eosin-stained section 
showed that the lesion had a neoplastic cell content of approximately 50%.  The 
Fluidigm access array was used to analyse 50 amplicons covering the hotspots 
reported in COSMIC (http://cancer.sanger.ac.uk) in 11 genes (EGFR, KRAS, BRAF, 
TP53, PTEN, NRAS, c-KIT, IDH1, IDH2, PDGFRA and PIK3CA), and sequencing 
was performed using the Ion Torrent Personal Genome Machine (PGM) (Life 
Technologies). An NRAS mutation was identified using the Integrative Genomics 
Viewer (IGV); a mutation was deemed present on the basis of a 35% base 
substitution with a ≥500 read depth. A substitution mutation was identified in NRAS 
codon 61, c.182A>G, causing an amino acid change from glutamine to arginine, 
p.Q61R (NCBI Reference Sequence: NG_007572.1; COSMIC mutation ID 
COSM584). No mutations were detected in BRAF (Figure 2) or any of the other 
genes.  
 
A molecular diagnosis can be valuable for providing a robust objective diagnosis and 
is particularly useful in this rare disease where the morphology can mimic a spectrum 
of reactive conditions. Genetic alterations in ECD are also important for guiding 
patient management because the identification of a BRAF V600E substitution in such 
patients, even with multisystemic disease which is refractory to first-line interferon-α 
treatment has been shown to respond to the BRAF inhibitor vemurafenib (4). In 
contrast, ECD harbouring an NRAS mutation would not be expected to respond to 
such targeted therapy.  Although direct inhibition of NRAS has proven difficult, the 
downstream mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-
kinases (PI3K) pathways are potential targets and MEK inhibitors, which act on the 
MAPK pathway, have been used successfully in NRAS-mutated melanoma and may 
therefore be useful in other NRAS-dependent neoplastic diseases.  
 
This case highlights the value of being able to provide a robust tissue diagnosis in 
addition to identifying mutations that could be exploited for targeted therapy or in this 
case deciding not to provide a targeted therapy from which most cases of ECD would 
benefit. This report of the second NRAS mutation in ECD argues for the need for 
more extensive multi-gene mutation profiling in addition to BRAF in patients with 
ECD. More research is warranted to reveal if the current findings have therapeutic 
consequences, but this time- and cost-efficient DNA sequencing technology may 
enable new therapeutic options in otherwise rare and devastating diseases with 
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(A-C) Photomicrographs of sclerotic intramedullary lesions showing diffuse chronic 
macrophagic infiltration of bone with bone remodelling. (A) H&E, scale bar equals 
500μm (B) H&E, scale bar equals 200μm; (C) H&E, scale bar equals 100μm. (D) 
Anteroposterior radiograph of the right knee.  Areas of increased density are seen in 
the right femur and tibia (arrows), in addition to osteoarthritis.  (E) Sagittal T1-
weighted image of the right knee showing confluent areas of abnormal marrow signal 




IGV showing sequence of DNA extracted from the needle biopsy specimen taken 
from the presenting bony lesion in the right tibia.  (A) 35% substitution mutation in 
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